Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Non-Malignant Channel is supported with funding from Agios (Gold).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

BSH 2022 | The role of clinical trials in improving treatment options for SCD

John James • 4 Apr 2022
BSH 2022
Non-Malignant Sickle Cell Disease

John James, OBE, Sickle Cell Society, London, UK, briefly discusses treatment options for patients with sickle cell disease (SCD) and the role of the Sickle Cell Society in improving these. While there have been no recent developments in new treatments, Mr James highlights the benefit of the increasing number of clinical trials in this field, and their importance in providing SCD patients with improved therapeutic options. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.

More from John James

The LISTEN survey: motivators and barriers to participation in sickle cell disease clinical trials
2:51
The LISTEN survey: motivators and barriers to participation in sickle cell disease clinical trials
John James • 13 Oct 2025
The impact of the withdrawals of crizanlizumab and voxelotor on patients with SCD in the UK
5:43
The impact of the withdrawals of crizanlizumab and voxelotor on patients with SCD in the UK
John James • 13 Oct 2025
The work of the Sickle Cell Society: supporting patients and improving SCD research
4:24
The work of the Sickle Cell Society: supporting patients and improving SCD research
John James • 13 Oct 2025
An insight into the role of the Sickle Cell Society
2:05
An insight into the role of the Sickle Cell Society
John James • 4 Apr 2022

Related Videos

Importance of long-term surveillance after gene therapy in patients with hemophilia
5:45
Importance of long-term surveillance after gene therapy in patients with hemophilia
Radek Kaczmarek • 20 Jul 2026
Emerging non-AAV gene therapy strategies in hemophilia: opportunities and challenges
4:58
Emerging non-AAV gene therapy strategies in hemophilia: opportunities and challenges
Radek Kaczmarek • 20 Jul 2026
Ongoing challenges associated with using AAV-based gene therapy in hemophilia
5:18
Ongoing challenges associated with using AAV-based gene therapy in hemophilia
Radek Kaczmarek • 20 Jul 2026
Understanding potential malignancy risk following AAV gene therapy in hemophilia
7:23
Understanding potential malignancy risk following AAV gene therapy in hemophilia
Radek Kaczmarek • 20 Jul 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals